AI Article Synopsis
- There is a significant need for better staging methods for non-small-cell lung cancer (NSCLC) to address high rates of recurrence and mortality after surgery, particularly due to undetectable metastases.
- A validated 14-gene quantitative PCR expression profile has shown to be more effective in identifying high-risk patients for 5-year mortality compared to traditional staging methods.
- Recent studies indicate that using this gene expression assay can improve disease-free survival when it informs adjuvant chemotherapy choices for early-stage NSCLC patients.
Article Abstract
There remains a critical need for improved staging of non-small-cell lung cancer, as recurrence and mortality due to undetectable metastases at the time of surgery remain high even after complete resection of tumors currently categorized as 'early stage.' A 14-gene quantitative PCR-based expression profile has been extensively validated to better identify patients at high-risk of 5-year mortality after surgical resection than conventional staging - mortality that almost always results from previously undetectable metastases. Furthermore, prospective studies now suggest a predictive benefit in disease-free survival when the assay is used to guide adjuvant chemotherapy decisions in early-stage non-small-cell lung cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039775 | PMC |
| http://dx.doi.org/10.2217/fon-2021-0517 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!